IMMP
Immutep
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
Three Black Crows
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About IMMP
Immutep Limited
A biotech company that develops novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease
Biological Technology
05/21/1987
04/16/2012
NASDAQ Stock Exchange
44
06-30
Depository Receipts (Ordinary Shares)
Level 32, Australia Square, 264 George Street, Sydney 2000, New South Wales, Australia
Biotechnology and Medical Research
Immutep Limited was incorporated in Australia on 21 May 1987. The company is a late-stage biotechnology company developing novel LAG-3-related immunotherapies for the treatment of cancer and autoimmune diseases. They are pioneers in understanding and advancing therapeutic approaches associated with lymphocyte activation gene -3 (LAG-3). Their diverse product portfolio leverages the unique ability of LAG-3 to regulate the body's immune response. Immutep is committed to leveraging its expertise to provide innovative treatment options to patients in need.
Company Financials
EPS
IMMP has released its 2022 Q2 earnings. EPS was reported at -0.02, versus the expected 0.00, missing expectations. The chart below visualizes how IMMP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available